T0	KEYPHRASE-NOTYPES 7 17	experience
T1	KEYPHRASE-NOTYPES 24 32	patients
T2	KEYPHRASE-NOTYPES 51 58	courses
T3	KEYPHRASE-NOTYPES 62 80	antibiotic therapy
T4	KEYPHRASE-NOTYPES 85 104	effective treatment
T5	KEYPHRASE-NOTYPES 108 122	Lyme arthritis
T6	KEYPHRASE-NOTYPES 127 133	] Thus
T7	KEYPHRASE-NOTYPES 147 175	mild residual joint swelling
T8	KEYPHRASE-NOTYPES 184 197	30-day course
T9	KEYPHRASE-NOTYPES 201 217	oral antibiotics
T10	KEYPHRASE-NOTYPES 233 256	oral antibiotic regimen
T11	KEYPHRASE-NOTYPES 272 276	days
T12	KEYPHRASE-NOTYPES 291 299	patients
T13	KEYPHRASE-NOTYPES 321 354	moderate-to-severe joint swelling
T14	KEYPHRASE-NOTYPES 363 376	30-day course
T15	KEYPHRASE-NOTYPES 380 396	oral antibiotics
T16	KEYPHRASE-NOTYPES 412 426	IV ceftriaxone
T17	KEYPHRASE-NOTYPES 432 435	day
T18	KEYPHRASE-NOTYPES 455 460	trend
T19	KEYPHRASE-NOTYPES 476 484	efficacy
T20	KEYPHRASE-NOTYPES 492 497	weeks
T21	KEYPHRASE-NOTYPES 514 519	weeks
T22	KEYPHRASE-NOTYPES 523 534	antibiotics
T23	KEYPHRASE-NOTYPES 560 569	frequency
T24	KEYPHRASE-NOTYPES 573 587	adverse events
T25	KEYPHRASE-NOTYPES 601 609	practice
T26	KEYPHRASE-NOTYPES 628 641	4-week course
T27	KEYPHRASE-NOTYPES 645 655	IV therapy
T28	KEYPHRASE-NOTYPES 676 683	patient
T29	KEYPHRASE-NOTYPES 722 735	complications
T30	KEYPHRASE-NOTYPES 752 760	patients
T31	KEYPHRASE-NOTYPES 783 794	improvement
T32	KEYPHRASE-NOTYPES 800 816	oral doxycycline
T33	KEYPHRASE-NOTYPES 839 859	moderate improvement
T34	KEYPHRASE-NOTYPES 868 887	complete resolution
T35	KEYPHRASE-NOTYPES 891 900	arthritis
T36	KEYPHRASE-NOTYPES 906 916	IV therapy
T37	KEYPHRASE-NOTYPES 947 976	persistent joint inflammation
T38	KEYPHRASE-NOTYPES 982 991	synovitis
T39	KEYPHRASE-NOTYPES 1014 1024	IV therapy
T40	KEYPHRASE-NOTYPES 1030 1044	decreased size
T41	KEYPHRASE-NOTYPES 1048 1057	effusions
T42	KEYPHRASE-NOTYPES 1062 1099	continued synovial tissue hypertrophy
T43	KEYPHRASE-NOTYPES 1104 1116	inflammation
T44	KEYPHRASE-NOTYPES 1118 1125	Courses
T45	KEYPHRASE-NOTYPES 1144 1148	days
T46	KEYPHRASE-NOTYPES 1152 1166	IV antibiotics
T47	KEYPHRASE-NOTYPES 1236 1245	frequency
T48	KEYPHRASE-NOTYPES 1249 1263	adverse effect
T49	KEYPHRASE-NOTYPES 1268 1282	] Additionally
T50	KEYPHRASE-NOTYPES 1286 1305	recent double-blind
T51	KEYPHRASE-NOTYPES 1319 1343	placebo-controlled study
T52	KEYPHRASE-NOTYPES 1347 1355	patients
T53	KEYPHRASE-NOTYPES 1359 1365	Europe
T54	KEYPHRASE-NOTYPES 1381 1388	benefit
T55	KEYPHRASE-NOTYPES 1392 1427	additional oral amoxicillin therapy
T56	KEYPHRASE-NOTYPES 1438 1447	treatment
T57	KEYPHRASE-NOTYPES 1453 1467	IV ceftriaxone
T58	KEYPHRASE-NOTYPES 1472 1473	]
T59	KEYPHRASE-NOTYPES 1476 1482	number
T60	KEYPHRASE-NOTYPES 1492 1508	oral antibiotics
T61	KEYPHRASE-NOTYPES 1515 1518	FDA
T62	KEYPHRASE-NOTYPES 1528 1540	drug library
T63	KEYPHRASE-NOTYPES 1552 1562	daptomycin
T64	KEYPHRASE-NOTYPES 1564 1574	carbomycin
T65	KEYPHRASE-NOTYPES 1580 1592	cefoperazone
T66	KEYPHRASE-NOTYPES 1625 1633	efficacy
T67	KEYPHRASE-NOTYPES 1653 1664	spirochetes
T68	KEYPHRASE-NOTYPES 1668 1675	culture
T69	KEYPHRASE-NOTYPES 1680 1681	]
T70	KEYPHRASE-NOTYPES 1714 1730	antibiotics
T71	KEYPHRASE-NOTYPES 1753 1761	patients
T72	KEYPHRASE-NOTYPES 1767 1781	Lyme arthritis
